{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:00:07Z","timestamp":1790758807744,"version":"4.1.0"},"reference-count":47,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Henan Province Clinical Research Physician Training Program","award":["HNCRD202430"],"award-info":[{"award-number":["HNCRD202430"]}]},{"name":"Key Research and Development Program of Henan Province","award":["251111312700"],"award-info":[{"award-number":["251111312700"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) after first-line failure remain limited, particularly in patients previously exposed to immune checkpoint inhibitors (ICIs). We evaluated the efficacy, safety, and exploratory biomarker correlates of camrelizumab, an ICI, combined with nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, as second-line therapy for ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, single-arm, phase II study, patients with advanced ESCC who progressed after first-line therapy received camrelizumab (200 mg every 2 weeks) plus nimotuzumab (400 mg weekly). The primary endpoint was the objective response rate (ORR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between November 2021 and December 2024, 46 patients were enrolled. The confirmed ORR was 32.6% (15\/46; 95% CI 19.5 to 48.0) and the disease control rate was 82.6% (38\/46; 95% CI 68.6 to 92.2). Median progression-free survival (PFS) was 9.13 months (95% CI 5.95 to 9.76), and median overall survival (OS) was 12.62 months (95% CI 9.40 to 15.01). Clinical activity was observed across subgroups, including immunotherapy-na\u00efve and previously treated patients (ORR 32.0% vs 33.3%). Patients with EGFR amplification demonstrated a higher ORR (47.1% vs 24.0%) and longer median OS (13.17 vs 9.99 months). Among patients with M1 disease (n=39), the ORR was 30.8% (95% CI 17.0 to 47.6), the median PFS was 8.48 months (95% CI 5.95 to 9.59), and the median OS was 12.55 months (95% CI 7.95 to 14.88). Treatment-related adverse events occurred in 80.4% of patients, with grade \u22653 events in 8.7%. Exploratory analyses suggested that\n                      <jats:italic>MUC16<\/jats:italic>\n                      mutations were associated with lower ORR (8.3% vs 46.4%, p=0.030),\n                      <jats:italic>NOTCH3<\/jats:italic>\n                      mutations with prolonged survival (median PFS not reached vs 8.21 months, HR 0.20, p=0.015; median OS not reached vs 10.58 months, HR 0.22, p=0.026), and\n                      <jats:italic>MTAP<\/jats:italic>\n                      deletions with shorter PFS (3.71 vs 9.49 months, HR 3.18, p=0.005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Camrelizumab combined with nimotuzumab demonstrated encouraging antitumor activity and a manageable safety profile as second-line therapy for advanced ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03766178\">NCT03766178<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015887","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:00:40Z","timestamp":1788868840000},"page":"e015887","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03766178","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03766178","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jin","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Anyang Tumor Hospital & The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China"},{"name":"State Key Laboratory of Metabolic Dysregulation & The Prevention and Treatment of Esophageal Cancer, Zhengzhou, China"},{"name":"Tianjian Laboratory for Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrui","family":"Meng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation & The Prevention and Treatment of Esophageal Cancer, Zhengzhou, China"},{"name":"Tianjian Laboratory for Advanced Biomedical Sciences, Zhengzhou, China"},{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggui","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Anyang Tumor Hospital & The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Anyang Tumor Hospital & The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xinyang Tumor Hospital, Xinyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghai","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Anyang Tumor Hospital & The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Anyang Tumor Hospital & The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzheng","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-7989","authenticated-orcid":false,"given":"Yao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Anyang Tumor Hospital & The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Anyang Tumor Hospital & The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangli","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaosheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongqiang","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xinyang Tumor Hospital, Xinyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiying","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quante","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongjin","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation & The Prevention and Treatment of Esophageal Cancer, Zhengzhou, China"},{"name":"Tianjian Laboratory for Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-5943","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation & The Prevention and Treatment of Esophageal Cancer, Zhengzhou, China"},{"name":"Tianjian Laboratory for Advanced Biomedical Sciences, Zhengzhou, China"},{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026093001151565000_14.9.e015887.1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0643"},{"key":"2026093001151565000_14.9.e015887.2","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"2026093001151565000_14.9.e015887.3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i26.7933"},{"key":"2026093001151565000_14.9.e015887.4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrgastro.2017.162","article-title":"Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends","volume":"15","author":"van Rossum","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026093001151565000_14.9.e015887.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30110-8"},{"key":"2026093001151565000_14.9.e015887.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6"},{"key":"2026093001151565000_14.9.e015887.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888"},{"key":"2026093001151565000_14.9.e015887.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28408-3","article-title":"Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)","volume":"13","author":"Xu","year":"2022","journal-title":"Nat Commun"},{"key":"2026093001151565000_14.9.e015887.9","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026093001151565000_14.9.e015887.10","doi-asserted-by":"crossref","first-page":"114328","DOI":"10.1016\/j.ejca.2024.114328","article-title":"Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study","volume":"212","author":"Meng","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026093001151565000_14.9.e015887.11","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.21037\/jtd.2018.09.18","article-title":"A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification","volume":"10","author":"Zhu","year":"2018","journal-title":"J Thorac Dis"},{"key":"2026093001151565000_14.9.e015887.12","first-page":"450","article-title":"Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas","volume":"125","author":"Yang","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"2026093001151565000_14.9.e015887.13","doi-asserted-by":"crossref","first-page":"S1472","DOI":"10.1016\/j.annonc.2022.10.133","article-title":"97P BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma","volume":"33","author":"Chiang","year":"2022","journal-title":"Annals of Oncology"},{"key":"2026093001151565000_14.9.e015887.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102172"},{"key":"2026093001151565000_14.9.e015887.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.008"},{"key":"2026093001151565000_14.9.e015887.16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cac2.12621","article-title":"HLX07 alone or combined with serplulimab, cisplatin and 5\u2010fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study","volume":"44","author":"Liu","year":"2024","journal-title":"Cancer Commun"},{"key":"2026093001151565000_14.9.e015887.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00136-4"},{"key":"2026093001151565000_14.9.e015887.18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1273798","article-title":"Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score \u2265 2: a retrospective study","volume":"13","author":"Wu","year":"2023","journal-title":"Front Oncol"},{"key":"2026093001151565000_14.9.e015887.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.023"},{"key":"2026093001151565000_14.9.e015887.20","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2203"},{"key":"2026093001151565000_14.9.e015887.21","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026093001151565000_14.9.e015887.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"2026093001151565000_14.9.e015887.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0638-6","article-title":"Correction to: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"2026093001151565000_14.9.e015887.24","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3123"},{"key":"2026093001151565000_14.9.e015887.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.7116"},{"key":"2026093001151565000_14.9.e015887.26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00382","article-title":"Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients","volume":"8","author":"Mazorra","year":"2017","journal-title":"Front Pharmacol"},{"key":"2026093001151565000_14.9.e015887.27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2018.04.008","article-title":"Nimotuzumab: beyond the EGFR signaling cascade inhibition","volume":"45","author":"Mazorra","year":"2018","journal-title":"Semin Oncol"},{"key":"2026093001151565000_14.9.e015887.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.02.020"},{"key":"2026093001151565000_14.9.e015887.29","article-title":"Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial","volume":"3","author":"Lu","year":"2022","journal-title":"Innovation (Camb)"},{"key":"2026093001151565000_14.9.e015887.30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/cac2.12546","article-title":"Converting \u201ccold\u201d to \u201chot\u201d: epigenetics strategies to improve immune therapy effect by regulating tumor\u2010associated immune suppressive cells","volume":"44","author":"Tang","year":"2024","journal-title":"Cancer Commun"},{"key":"2026093001151565000_14.9.e015887.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026093001151565000_14.9.e015887.32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"7","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026093001151565000_14.9.e015887.33","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae245","article-title":"Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study","volume":"30","author":"Hong","year":"2025","journal-title":"Oncologist"},{"key":"2026093001151565000_14.9.e015887.34","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.792779","article-title":"Integrative Genomic Analyses of 1,145 Patient Samples Reveal New Biomarkers in Esophageal Squamous Cell Carcinoma","volume":"8","author":"Zou","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026093001151565000_14.9.e015887.35","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7228","article-title":"Molecular and immunological characteristics of postoperative relapse in lymph node-positive esophageal squamous cell cancer","volume":"13","author":"Pan","year":"2024","journal-title":"Cancer Med"},{"key":"2026093001151565000_14.9.e015887.36","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.7150\/jca.68568","article-title":"Identification and analysis of a prognostic ferroptosis and iron-metabolism signature for esophageal squamous cell carcinoma","volume":"13","author":"Zhao","year":"2022","journal-title":"J Cancer"},{"key":"2026093001151565000_14.9.e015887.37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.040"},{"key":"2026093001151565000_14.9.e015887.38","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1002\/cam4.3933","article-title":"NOTCH3 limits the epithelial-mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer","volume":"10","author":"Matsuura","year":"2021","journal-title":"Cancer Med"},{"key":"2026093001151565000_14.9.e015887.39","doi-asserted-by":"crossref","first-page":"713","DOI":"10.21037\/atm-21-1317","article-title":"Integrated genomic and transcriptomic analysis suggests KRT18 mutation and MTAP are key genetic alterations related to the prognosis between astrocytoma and glioblastoma","volume":"9","author":"Li","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026093001151565000_14.9.e015887.40","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"key":"2026093001151565000_14.9.e015887.41","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13587"},{"key":"2026093001151565000_14.9.e015887.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-10157-0","article-title":"MTAP deficiency is highly homogeneous in advanced, muscle-invasive urothelial carcinoma of the urinary bladder","volume":"15","author":"Gorbokon","year":"2025","journal-title":"Sci Rep"},{"key":"2026093001151565000_14.9.e015887.43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-1507"},{"key":"2026093001151565000_14.9.e015887.44","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.101977","article-title":"Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma","volume":"6","author":"Mu","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026093001151565000_14.9.e015887.45","first-page":"1136","article-title":"Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma","volume":"92","author":"Sunpaweravong","year":"2009","journal-title":"J Med Assoc Thai"},{"key":"2026093001151565000_14.9.e015887.46","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3892\/ol.2015.3277","article-title":"Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma","volume":"10","author":"Lin","year":"2015","journal-title":"Oncol Lett"},{"key":"2026093001151565000_14.9.e015887.47","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.1830"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:15:44Z","timestamp":1790756144000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015887"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015887","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}